Trial Profile

Phase II study of gemcitabine, carboplatin and dexamethasone with or without rituximab for patients with relapsed or refractory non-Hodgkin's lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Carboplatin; Dexamethasone; Gemcitabine
Indications Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms GHG-GCD

Most Recent Events

01 Jan 2024 Status has been changed to completed.
01 Jan 2024 Results of efficacy and safety of salvage chemotherapy with gemcitabine, carboplatin, dexamethasone, and rituximab , published in the Hematological Oncology
23 Dec 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com